Rani Therapeutics elects Lisa Rometty to board of directors

Rani Therapeutics Holdings, Inc.

Lisa Rometty elected director effective Jan 3, 2022; term expires at next annual meeting.
Granted nonqualified stock options for 49,037 shares at $17.00 exercise price, vesting over 3 years.
Compensation per standard non-employee director policy; standard indemnification agreement executed.
No arrangement or understanding with others for election; no related-party transactions disclosed.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Lisa Rometty

Director

RANI · Rani Therapeutics Holdings, Inc.

Effective: 2022-01-03
Filed: January 5, 2022, 6:59 PM ET

On January 2, 2022, upon the recommendation of its Nominating and Corporate Governance Committee, the board of directors (the “Board”) of Rani Therapeutics Holdings, Inc. (the “Company”) elected Lisa Rometty as a director of the Company, effective January 3, 2022, with a term expiring at the Company’s next annual meeting of stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Lisa Rometty was elected as Director at Rani Therapeutics Holdings, Inc..

Action: elected
Role: Director

Exact text from the filing

On January 2, 2022, upon the recommendation of its Nominating and Corporate Governance Committee, the board of directors (the “Board”) of Rani Therapeutics Holdings, Inc. (the “Company”) elected Lisa Rometty as a director of the Company, effective January 3, 2022, with a term expiring at the Company’s next annual meeting of stockholders.

View on SEC.gov

Rani Therapeutics Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-002651

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.